치료 없는 생존: 면역 관문 억제 효과의 새로운 결과 지표—진행성 흑색종 환자에 대한 통합 분석

Regan 등(Mon,)이 이 문제를 연구하였다.

www.synapsesocial.com/papers/69d91684d8690e49a78358b8 — DOI: https://doi.org/10.1200/jco.19.00345

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. High-Dose Recombinant Interleukin 2 Therapy for Patients With Metastatic Melanoma: Analysis of 270 Patients Treated Between 1985 and 1993· 1999 · 2,029 citations
2. Evaluating Treatment Effect Based on Duration of Response for a Comparative Oncology Study· 2018 · 41 citations
3. Treatment-free interval as a metric of patient experience and a health outcome of value for advanced multiple myeloma: the case for the histone deacetylase inhibitor panobinostat, a next-generation novel agent· 2017 · 11 citations
4. Intermediate clinical endpoints: A bridge between progression‐free survival and overall survival in ovarian cancer trials· 2014 · 85 citations
5. Immunotherapy combinations transform the treatment paradigm for advanced renal cell carcinoma· 2019 · 5 citations